Red Propolis Supplementation as a Strategy in Chronic Kidney Disease

Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07597005

Enrollment

Registered

2026-05-19

Start date

2025-09-30

Completion date

2027-08-31

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Inflammation, Kidney Disease, Oxidative Stress

Keywords

oxidative stress, red propolis, inflammation, chronic kidney disease

Brief summary

The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.

Detailed description

Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.

Interventions

DIETARY_SUPPLEMENTRed Propolis

Participants will receive 200mg of red propolis capsules per day for two months.

OTHERPlacebo Control

Participants will receive 200mg of placebo capsules per day for two months.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients with CKD stages 3-5 under conservative management

Exclusion criteria

* pregnant, * lactating, * smoker * patients using antibiotics and antioxidant supplements in the last three months * patients with autoimmune and infectious diseases, * patients with cancer, liver disease, and AIDS

Design outcomes

Primary

Measure	Time frame	Description
Change in inflammatory biomarkers	8 weeks	Changes in the IL-6 and TNF-α

Countries

Brazil

Contacts

CONTACTDenise Mafra, phd

dmafra30@gmail.com21985683003

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026